PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568406
PUBLISHER: Global Market Insights Inc. | PRODUCT CODE: 1568406
Antiemetics Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
The Global Antiemetics Drugs Market size is anticipated to grow at a 5.6% CAGR between 2024 and 2032, fueled by the rising prevalence of conditions like chemotherapy-induced nausea and vomiting (CINV), motion sickness, and gastrointestinal disorders. With advancements in cancer treatments becoming more prevalent, the demand for effective antiemetic drugs to manage CINV and enhance patient quality of life is surging. According to the National Institute of Health, approximately 15% to 70% of individuals experience CINV.
Newly introduced antiemetic drugs, especially those with targeted actions and minimized side effects, are broadening treatment avenues for patients. Heightened awareness, early diagnoses of nausea-related conditions, and a shift toward personalized medicine are set to propel market growth.
The antiemetics industry is divided into drug type, application, route of administration, distribution channel, and region.
Based on drug type, the antiemetics drugs market size from the anticholinergics segment is slated to witness a substantial growth rate during 2024-2032 due to its efficacy in managing nausea and vomiting, especially in motion sickness and post-operative recovery. The established effectiveness in curbing nausea and their wide-ranging application in medical scenarios, including both preoperative and postoperative contexts, will bolster the segment expansion.
Antiemetics drugs market from the gastroenteritis application segment will grow at a notable pace through 2032. Gastroenteritis leads to significant gastrointestinal distress, making effective antiemetic treatments crucial for managing symptoms and providing relief. As the prevalence of gastroenteritis remains notable worldwide, the demand for antiemetic drugs to treat and manage the associated nausea and vomiting will drive market growth.
Asia Pacific antiemetics drugs industry is projected to generate lucrative opportunities during 2024-2032. The expanding healthcare infrastructure, coupled with a burgeoning population and a heightened prevalence of diseases requiring effective antiemetic treatments, underscores this growth. Furthermore, advancements in pharmaceutical R and D and increasing awareness and accessibility of innovative antiemetic therapies are further energizing the regional market.
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market scope and definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360° synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising prevalence of nausea and vomiting-inducing conditions
- 3.2.1.2 Growing availability of reimbursement and coverage for antiemetic drugs
- 3.2.1.3 Advancements in drug formulations
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 Side effects and safety concerns
- 3.2.2.2 Stringent regulatory scenario
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.5.1 Core technologies
- 3.5.2 Adjacent technologies
- 3.6 Future market trends
- 3.7 Gap analysis
- 3.8 Porter's analysis
- 3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Company matrix analysis
- 4.4 Competitive analysis of major market players
- 4.5 Competitive positioning matrix
- 4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Serotonin-receptor antagonists
- 5.3 Anticholinergics
- 5.4 Glucocorticoids
- 5.5 Dopamine receptor antagonists
- 5.6 Neurokinin receptor antagonists
- 5.7 Antihistamines
- 5.8 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Chemotherapy induced nausea and vomiting (CINV)
- 6.3 Gastroenteritis
- 6.4 Postoperative nausea and vomiting (PONV)
- 6.5 Other applications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oral
- 7.3 Parenteral
- 7.4 Other routes of administration
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Hospital pharmacies
- 8.3 Retail pharmacies
- 8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Spain
- 9.3.5 Italy
- 9.3.6 Netherlands
- 9.3.7 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 South Africa
- 9.6.2 Saudi Arabia
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Astellas Pharma Inc.
- 10.2 Baxter International Inc.
- 10.3 Cipla Limited
- 10.4 Eagle Pharmaceuticals, Inc.
- 10.5 Glenmark Pharmaceuticals Limited
- 10.6 GSK plc
- 10.7 Hikma Pharmaceuticals PLC
- 10.8 Johnson and Johnson
- 10.9 Merck and Co., Inc.
- 10.10 Novartis AG
- 10.11 Pfizer Inc.
- 10.12 Takeda Pharmaceutical Company Limited
- 10.13 Teva Pharmaceutical Industries Limited
- 10.14 Torrent Pharmaceuticals Limited
- 10.15 Viatris Inc.
